Why Population Studies Don't Answer Your Question
A randomized controlled trial showing that magnesium improves sleep in adults ages 30–65 tells you one thing: on average, across a sample of people who fit that description, magnesium appeared to improve sleep compared to placebo. It does not tell you whether magnesium will improve your sleep.
You are not the average. Your genetics, gut microbiome, baseline nutrient status, stress load, and sleep architecture are all specific to you. Population statistics describe groups. You need data about an individual — yourself.
This is the rationale behind N-of-1 experimental design.
Related: Want to put this into practice? Try our Experiment Builder to get started, and check out 30-Day Sleep Experiment: Optimize Bedtime With Data for more context.
What N=1 Means Formally
N=1 refers to a single-subject experimental design where one individual serves as their own control. Rather than comparing a treatment group to a placebo group across hundreds of people, you compare your own active-treatment periods to your own baseline or washout periods.
The formal academic version uses statistical methods to analyze single-subject data — including tests for serial correlation, effect size estimation, and time-series analysis. The practical self-tracker version doesn't need most of that. But understanding the underlying logic makes you a better interpreter of your own data.
The key insight is this: in an N=1 design, individual variability isn't a problem to be averaged away — it's the point. You're interested in your variability and whether an intervention shifts it.
ABA and ABAB Designs
The most common N=1 structure is the ABA design:
- A (Baseline): Track without the intervention. Establish your normal range.
- B (Active): Introduce the intervention. Continue tracking the same metrics.
- A (Reversal/Washout): Remove the intervention. Track whether metrics return toward baseline.
The second A phase is critical. If your metrics improved during B and then declined when you removed the intervention, you have meaningful evidence of a causal relationship — not just a correlation. If metrics stay elevated during the second A phase, the effect may be cumulative, or it may have been driven by something other than the supplement.
ABAB design (stronger evidence):
- A: Baseline (14 days)
- B: Active (28 days)
- A: Washout (14 days)
- B: Reintroduce (28 days)
The ABAB design replicated the active phase. If your metrics improve in both B periods and soften in both A periods, you have considerably stronger evidence than a single A/B comparison. The trade-off is time — this design takes 10-12 weeks minimum.
How Many Data Points Do You Need?
Statistical power in N=1 designs comes from repeated measurements over time, not from more participants. A single time point has no inferential value. A week of data lets you see daily variation. Three weeks of data gives you enough to start identifying trends and outliers.
A general rule of thumb for self-trackers:
| Phase | Minimum Data Points | Preferred |
|---|---|---|
| Baseline | 7 days | 14 days |
| Active phase | 21 days | 28-30 days |
| Washout/reversal | 7 days | 14 days |
More data is always better, up to a point. The limiting factor isn't usually statistical — it's compliance. A 90-day rigidly controlled experiment that you abandon at day 45 is worse than a clean 28-day experiment you complete.
Understanding Variance and Effect Size
Your metrics vary naturally from day to day. HRV can swing 10-15ms between similar nights. Sleep scores fluctuate 5-10 points without any intervention. Subjective ratings are even noisier.
This natural variance is the background against which you need to detect a signal. An intervention that moves your average HRV by 2ms against a background of 12ms daily fluctuation is not detectable with a short experiment. An intervention that moves your average by 8ms against the same background is more visible — though still noisy.
Effect size refers to how large the change is relative to the natural variation. A large effect size (a big shift relative to your normal fluctuation) is detectable with shorter experiments and fewer data points. A small effect size requires longer experiments and cleaner conditions to distinguish from noise.
Calculate your natural variance during baseline: take the standard deviation of your baseline measurements. As a rough guide, a meaningful active-phase change is one where the average shifts by at least half of one standard deviation. If your baseline HRV has a standard deviation of 10ms, you're looking for an average shift of 5ms or more to consider it potentially meaningful.
Serial Correlation: The Hidden Problem
One challenge specific to N=1 designs is that time-series data tends to be autocorrelated — meaning yesterday's HRV predicts today's HRV to some degree. This violates the assumption of independence in standard statistical tests.
You don't need to run formal autocorrelation tests to self-experiment usefully. But you should understand the implication: a single-night outlier will affect the following days' data not just because of what happened physically, but because of how time-series data naturally behaves. This is another reason why 7-day rolling averages are more informative than single-day readings for most self-tracking purposes.
When comparing baseline to active phase, compare week-over-week averages rather than individual days. This smooths out the serial correlation and gives you more stable comparison points.
When N=1 Is Most and Least Useful
N=1 designs are most valuable for:
- Questions about your personal response to a supplement or intervention
- Dose optimization — finding the amount that works for you
- Identifying responders vs. non-responders (you can discover if you're in the group that responds to a given compound)
- Validating population-level findings at the individual level
N=1 designs are less useful for:
- Generalizing to others — your results apply to you, not to anyone else
- Small effect sizes — subtle effects require much larger sample sizes or longer experiments than most people will sustain
- Rapidly changing baselines — if your health metrics are inherently unstable (due to ongoing illness, major lifestyle transition, or significant ongoing stress), separating intervention effects from background noise is very difficult
- Interactions between multiple variables — the more simultaneous changes you have, the harder any single-subject design becomes
N=1 data is most powerful when it confirms or contradicts a finding from population research. If a meta-analysis suggests that compound X improves outcome Y by 10% on average, and your personal experiment suggests a similar direction and magnitude, you have a personally validated reason to include it in your protocol.
Applying the Framework Practically
You don't need to be a statistician to run a good N=1 experiment. The key practices are:
- Define your outcome metric and success threshold before you start
- Use enough data points in each phase — minimum 14 days of baseline, 21 days of active
- Keep everything else as stable as possible across phases
- Compare weekly averages, not individual days
- Use a reversal phase if you want stronger evidence
- Interpret results in light of natural variance — small shifts in noisy metrics are weak evidence
The goal isn't perfect statistical rigor. It's honest, structured self-observation that produces actionable conclusions — conclusions that hold up over repeated experiments and tell you something reliable about your own biology. For a practical overview of how to apply this to supplements specifically, see the Complete Guide to Supplement Tracking.
Be the first to try Prova
We're building an app to track whether N=1 self-experimentation actually works. Join the waitlist.